Sus Clinicals

Executive Summary

Sus Clinicals, founded in 2018 and headquartered in San Diego, is a preclinical-stage biotechnology company specializing in a proprietary pig-based preclinical testing platform (Oncopigs) designed to accelerate the qualification of cancer therapeutics. The company's approach leverages large animal models to better predict human clinical outcomes, aiming to reduce the high attrition rates in oncology drug development. By collaborating with top research institutions, Sus Clinicals offers a unique service that identifies drugs, diagnostics, and devices with the highest probability of success in human trials. This platform addresses a critical gap in the drug development pipeline, potentially saving time and costs by filtering out less promising candidates earlier. Despite its innovative value proposition, the company is still in early stages with no disclosed funding rounds, partnerships, or clinical milestones. Its success hinges on validating the predictive accuracy of its model and securing partnerships to gain credibility and financial runway.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data readout from ongoing pig model studies40% success
• Q2 2027Strategic partnership with a major pharmaceutical or CRO30% success
• Q3 2026Series A funding round closure50% success